RxDoctor Payments DataLook up a doctor →

Maureen Li, MD

Neurology · Crestview Hills, KYNPI 1346359387

Payments from drug & device makers

$16,028in general payments, 2019–2025

Across 804 payments — averaging $19.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$2K
  • AbbVie$2K
  • UCB, Inc.$1K
  • Lilly USA, LLC$705
  • SK Life Science, Inc.$612
  • AstraZeneca$572
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$2241%
  • Food & beverage$15,49797%
  • Education$3082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Sanofi44$1,582
AbbVie(2 entities)112$1,538
UCB, Inc.56$1,190
Lilly USA, LLC41$705
SK Life Science, Inc.17$612
AstraZeneca19$572
Teva Pharmaceuticals USA, Inc.40$547
Biogen26$530
Eisai Inc.17$530
Amneal Pharmaceuticals LLC28$513
Novartis39$496
Acadia Pharmaceuticals Inc17$443
Neurelis, Inc.15$412
Ipsen Biopharmaceuticals, Inc8$338
Jazz Pharmaceuticals Inc.11$335
Pfizer21$322
Acorda Therapeutics, Inc46$318
Lundbeck LLC13$296
Sunovion Pharmaceuticals Inc.13$290
Neurocrine Biosciences, Inc.9$279
Amgen9$276
Supernus Pharmaceuticals, Inc.42$246
MDD US Operations, LLC12$233
Biohaven Pharmaceutical Holding Company Ltd.9$232
Sanofi-aventis U.S. LLC5$228
Greenwich Biosciences, Inc.9$217
Kyowa Kirin, Inc.7$194
Avanir Pharmaceuticals, Inc.10$186
Catalyst Pharmaceuticals, Inc.3$176
EMD Serono, Inc.9$168
Axsome Therapeutics, Inc.6$160
Bristol Myers Squibb13$151
Biohaven Pharmaceuticals, Inc.4$148
Adamas Pharmaceuticals, Inc.3$147
Argenx US, Inc.6$145
Idorsia Pharmaceuticals US Inc3$137
Impel Pharmaceuticals Inc.1$108
Merz North America, Inc.3$66
Merz Pharmaceuticals, LLC2$62
Grifols USA, LLC3$60
Endo Pharmaceuticals Inc.3$54
Bausch Health US, LLC3$52
Averitas Pharma Inc.2$49
Aprecia Pharmaceuticals, LLC3$41
Assertio Therapeutics, Inc.3$40
Otsuka America Pharmaceutical, Inc.2$39
Vanda Pharmaceuticals Inc.2$35
Medtronic1$35
Insightec,inc2$33
Promius Pharma LLC2$33
GE HealthCare2$31
Alnylam Pharmaceuticals Inc.2$31
Vertical Pharmaceuticals, LLC2$27
Boston Scientific2$26
Cala Health, Inc.1$23
TG Therapeutics, Inc.1$22
Akcea Therapeutics, Inc.1$21
Livanova USA, Inc.1$21
Hospira, Inc.3$19
Corium, LLC1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,028 in reported general payments places this provider in the 70th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$129,703
Medicare patients
387
Services billed
7,710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a17$197,982
IngrezzaValbenazine Tosylate14$118,068
Avonex (4 Pack)Interferon Beta-1a14$115,722
AubagioTeriflunomide12$108,669
Nurtec OdtRimegepant Sulfate41$70,876
NuplazidPimavanserin Tartrate12$60,249
Dimethyl Fumarate11$58,927
GocovriAmantadine Hcl17$57,877
Aimovig AutoinjectorErenumab-Aooe46$51,667
KeppraLevetiracetam17$36,600
RytaryCarbidopa/Levodopa26$29,151
NourianzIstradefylline14$27,008
Emgality PenGalcanezumab-Gnlm17$25,441
UbrelvyUbrogepant19$24,086
Topiramate ErTopiramate16$18,105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$279$118,06814 claims
BiogenAvonex (4 Pack)$530$115,72214 claims
SanofiAubagio$1,582$108,66912 claims
PfizerNurtec Odt, Dilantin$322$74,57253 claims
Acadia Pharmaceuticals IncNuplazid$443$60,24912 claims
MDD US Operations, LLCGocovri$233$57,87717 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$513$33,89386 claims
Kyowa Kirin, Inc.Nourianz$194$27,00814 claims
AbbVieUbrelvy$1,538$24,08619 claims
Otsuka America Pharmaceutical, Inc.Rexulti$39$14,97811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 210 neurology providers in Kentucky.

Other neurology in Crestview Hills

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →